As Nuke said, it would be more logical to know before hand.
I believe this would disqualify you from clinical study.
With that said, testing for a specific tumor biomarker is less than uniform. There are several different assays that could be used, however at the moment there is no specific consensus. Opdivo has an uphill battle in regards to educating these qualifications for treatment.
News 
Market Data 
Discover 
AI
